Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.22USD
8:59pm GMT
Change (% chg)

$0.31 (+0.72%)
Prev Close
$42.91
Open
$42.67
Day's High
$43.38
Day's Low
$42.35
Volume
4,563,639
Avg. Vol
6,226,744
52-wk High
$45.81
52-wk Low
$33.20

Select another date:

Wed, Nov 14 2018

Photo

Pfizer loses drug patent fight in UK top court, may face claims

LONDON Pfizer lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims.

Pfizer loses drug patent fight in UK top court, may face claims

LONDON Pfizer lost the final round in a lengthy patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica, exposing the company to possible financial claims.

UPDATE 2-Pfizer loses drug patent fight in UK top court, may face claims

* Drugmaker says court decision a setback for innovation (Adds NHS, lawyer comment on possible claims against Pfizer)

Pfizer loses Lyrica drug patent fight in UK Supreme Court

LONDON, Nov 14 Pfizer lost the final round in a long-running patent battle in Britain on Wednesday after the country's highest court ruled against it in a case involving its $5 billion-a-year pain drug Lyrica.

FDA approves Pfizer's treatment for certain lung cancer patients

Pfizer Inc said on Friday the U.S. Food and Drug Administration has approved its lung-cancer treatment for patients with a specific gene mutation who had been previously treated for an aggressive form of the disease.

FDA approves Pfizer's treatment for certain lung cancer patients

Nov 2 Pfizer Inc said on Friday the U.S. Food and Drug Administration has approved its lung-cancer treatment for patients with a specific gene mutation who had been previously treated for an aggressive form of the disease.

Pfizer weighing sale of women's health portfolio - Bloomberg

U.S. drugmaker Pfizer Inc is considering options, including a sale of its women's health portfolio, Bloomberg reported on Thursday, citing sources familiar with the matter.

Pfizer weighing sale of women's health portfolio: Bloomberg

U.S. drugmaker Pfizer Inc is considering options, including a sale of its women's health portfolio, Bloomberg reported on Thursday, citing sources familiar with the matter.

Pfizer weighing sale of women's health portfolio - Bloomberg

Nov 1 U.S. drugmaker Pfizer Inc is considering options, including a sale of its women's health portfolio, Bloomberg reported on Thursday, citing sources familiar with the matter.

Pfizer revenue worse than expected as generic competition weighs

Pfizer Inc on Tuesday reported worse-than-expected third quarter revenue and lowered the top end of its full-year sales forecast as generic competition and drug pricing pressure in the United States hurt its older drugs business.

Select another date: